aluates Reports

$ 0.0

Automative

Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

Published Date: August 2025

Report Code: QYRE-Auto-12J9107

Global Irritable Bowel Syndrome with Diarrhea IBS D Drugs Market Outlook 2022

BUY CHAPTERS

Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

Code: QYRE-Auto-12J9107

Report

August 2025

Pages:80

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Bausch Health

Allergan plc

Sebela Pharmaceuticals

Astellas Pharmaceuticals

Amneal pharms

Pharscin Pharma

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Size

The global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size was US$ 1698 million in 2024 and is forecast to a readjusted size of US$ 3427 million by 2031 with a CAGR of 10.7% during the forecast period 2025-2031.

Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market

By 2025, the evolving U.S. tariff policy is poised to inject considerable uncertainty into the global economic landscape. This report delves into the latest U.S. tariff measures and the corresponding policy responses across the globe, evaluating their impacts on Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market competitiveness, regional economic performance, and supply chain configurations.

Irritable bowel syndrome (IBS) is a common disorder that affects the large intestine. Signs and symptoms include cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both. IBS is a chronic condition that need to manage long term.

IBS that causes increased diarrhea is often called IBS-D. Diarrhea predominant irritable bowel syndrome (IBS-D) is a subtype of IBS in which a person experiences frequent episodes of diarrhea with accompanying abdominal pain. Like IBS, IBS-D is a functional gastrointestinal disorder (FGD) in that there is no visible disease, inflammation, or injury to account for its symptoms. It is estimated that approximately a third of people who have IBS experience the disorder with diarrhea as the predominant bowel habit.

In this report, we study the drugs for diarrhea predominant irritable bowel syndrome (IBS-D).

North America is the largest consumption place of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, followed by Europe. The two account for more than 80% of the consumer market in together. The most used IBS-D drug is XIFAXAN, accounting for more than 60% of the market share, followed by Viberzi and Lotronex. IBS-D drugs are widely sold through hospital pharmacies and retail pharmacies.

The global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is strategically segmented by company, region (country), by Type, and by Sales Channel. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on sales, revenue, and forecasts across regions, by Type, and by Sales Channel for 2020-2031.

Market Segmentation

Scope of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Report

Report Metric	Details
Report Name	Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market
Forecasted market size in 2031	US$ 3427 million
CAGR	10.7%
Forecasted years	2025 - 2031
By Type: (Dominant Segment vs High-Margin Innovation)	XIFAXAN Viberzi Lotronex Other
By Application: (Core Demand Driver vs Emerging Opportunity)	Hospitals Pharmacy Retail Pharmacy Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company:	Bausch Health, Allergan, Sebela Pharmaceuticals, Astellas Pharmaceuticals, Amneal Pharms, Pharscin Pharma
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Viberzi in China).
Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Retail Pharmacy in India).
Chapter 6: Regional sales and revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
This is not just another market study. By fusing global trend analysis with hyper-local operational intelligence, we deliver:
- Risk-Controlled Market Entry: Navigate regulatory complexities in focus markets (e.g., China’s policies).
- Product Portfolio Optimization: Align offerings with regional preferences (e.g., XIFAXAN dominance in Europe vs. Viberzi demand in MEA).
- Competitor Counterstrategies: Decode player tactics in fragmented vs. consolidated markets.

FAQ for this report

What is the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market size in 2031?

Ans: The Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market size in 2031 will be US$ 3427 million.

Who are the main players in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market report?

Ans: The main players in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market are Bausch Health, Allergan, Sebela Pharmaceuticals, Astellas Pharmaceuticals, Amneal Pharms, Pharscin Pharma

What are the Application segmentation covered in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market report?

Ans: The Applications covered in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market report are Hospitals Pharmacy, Retail Pharmacy, Other

What are the Type segmentation covered in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market report?

Ans: The Types covered in the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market report are XIFAXAN, Viberzi, Lotronex, Other

1 Market Overview

1.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Scope

1.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Type

1.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2020 & 2024 & 2031)

1.2.2 XIFAXAN

1.2.3 Viberzi

1.2.4 Lotronex

1.2.5 Other

1.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Sales Channel

1.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Comparison by Sales Channel (2020 & 2024 & 2031)

1.3.2 Hospitals Pharmacy

1.3.3 Retail Pharmacy

1.3.4 Other

1.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Estimates and Forecasts (2020-2031)

1.4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size in Value Growth Rate (2020-2031)

1.4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size in Volume Growth Rate (2020-2031)

1.4.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price Trends (2020-2031)

1.5 Assumptions and Limitations

2 Market Size and Prospective by Region

2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size by Region: 2020 VS 2024 VS 2031

2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Retrospective Market Scenario by Region (2020-2025)

2.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2020-2025)

2.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region (2020-2025)

2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Estimates and Forecasts by Region (2026-2031)

2.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Estimates and Forecasts by Region (2026-2031)

2.3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Region (2026-2031)

2.4 Major Region and Emerging Market Analysis

2.4.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size and Prospective (2020-2031)

2.4.2 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size and Prospective (2020-2031)

2.4.3 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size and Prospective (2020-2031)

3 Global Market Size by Type

3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historic Market Review by Type (2020-2025)

3.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2020-2025)

3.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2020-2025)

3.1.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2020-2025)

3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Estimates and Forecasts by Type (2026-2031)

3.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Type (2026-2031)

3.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Type (2026-2031)

3.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price Forecast by Type (2026-2031)

3.3 Different Types Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Representative Players

4 Global Market Size by Sales Channel

4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Historic Market Review by Sales Channel (2020-2025)

4.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2020-2025)

4.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (2020-2025)

4.1.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Sales Channel (2020-2025)

4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Estimates and Forecasts by Sales Channel (2026-2031)

4.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Sales Channel (2026-2031)

4.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Forecast by Sales Channel (2026-2031)

4.2.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price Forecast by Sales Channel (2026-2031)

4.3 New Sources of Growth in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Application

5 Competition Landscape by Players

5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Players (2020-2025)

5.2 Global Top Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Players by Revenue (2020-2025)

5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs as of 2024)

5.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Company (2020-2025)

5.5 Global Key Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Manufacturing Sites & Headquarters

5.6 Global Key Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Product Type & Application

5.7 Global Key Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Date of Enter into This Industry

5.8 Manufacturers Mergers & Acquisitions, Expansion Plans

6 Region Analysis

6.1 North America Market: Players, Segments, Downstream and Major Customers

6.1.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Company

6.1.1.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Company (2020-2025)

6.1.1.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Company (2020-2025)

6.1.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Breakdown by Type (2020-2025)

6.1.3 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Breakdown by Sales Channel (2020-2025)

6.1.4 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Major Customer

6.1.5 North America Market Trend and Opportunities

6.2 Japan Market: Players, Segments, Downstream and Major Customers

6.2.1 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Company

6.2.1.1 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Company (2020-2025)

6.2.1.2 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Company (2020-2025)

6.2.2 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Breakdown by Type (2020-2025)

6.2.3 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Breakdown by Sales Channel (2020-2025)

6.2.4 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Major Customer

6.2.5 Japan Market Trend and Opportunities

6.3 China Market: Players, Segments, Downstream and Major Customers

6.3.1 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Company

6.3.1.1 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Company (2020-2025)

6.3.1.2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Company (2020-2025)

6.3.2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Breakdown by Type (2020-2025)

6.3.3 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Breakdown by Sales Channel (2020-2025)

6.3.4 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Major Customer

6.3.5 China Market Trend and Opportunities

7 Company Profiles and Key Figures

7.1 Bausch Health

7.1.1 Bausch Health Company Information

7.1.2 Bausch Health Business Overview

7.1.3 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2020-2025)

7.1.4 Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered

7.1.5 Bausch Health Recent Development

7.2 Allergan

7.2.1 Allergan Company Information

7.2.2 Allergan Business Overview

7.2.3 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2020-2025)

7.2.4 Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered

7.2.5 Allergan Recent Development

7.3 Sebela Pharmaceuticals

7.3.1 Sebela Pharmaceuticals Company Information

7.3.2 Sebela Pharmaceuticals Business Overview

7.3.3 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2020-2025)

7.3.4 Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered

7.3.5 Sebela Pharmaceuticals Recent Development

7.4 Astellas Pharmaceuticals

7.4.1 Astellas Pharmaceuticals Company Information

7.4.2 Astellas Pharmaceuticals Business Overview

7.4.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2020-2025)

7.4.4 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered

7.4.5 Astellas Pharmaceuticals Recent Development

7.5 Amneal Pharms

7.5.1 Amneal Pharms Company Information

7.5.2 Amneal Pharms Business Overview

7.5.3 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2020-2025)

7.5.4 Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered

7.5.5 Amneal Pharms Recent Development

7.6 Pharscin Pharma

7.6.1 Pharscin Pharma Company Information

7.6.2 Pharscin Pharma Business Overview

7.6.3 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Gross Margin (2020-2025)

7.6.4 Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered

7.6.5 Pharscin Pharma Recent Development

8 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Cost Analysis

8.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Key Raw Materials Analysis

8.1.1 Key Raw Materials

8.1.2 Key Suppliers of Raw Materials

8.2 Proportion of Manufacturing Cost Structure

8.3 Manufacturing Process Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs

8.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industrial Chain Analysis

9 Marketing Channel, Distributors and Customers

9.1 Marketing Channel

9.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors List

9.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers

10 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Dynamics

10.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industry Trends

10.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Drivers

10.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Challenges

10.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Restraints

11 Research Findings and Conclusion

12 Appendix

12.1 Research Methodology

12.1.1 Methodology/Research Approach

12.1.1.1 Research Programs/Design

12.1.1.2 Market Size Estimation

12.1.1.3 Market Breakdown and Data Triangulation

12.1.2 Data Source

12.1.2.1 Secondary Sources

12.1.2.2 Primary Sources

12.2 Author Details

12.3 Disclaimer

FEATURED COMPANIES

Bausch Health

Allergan plc

Sebela Pharmaceuticals

Astellas Pharmaceuticals

Amneal pharms

Pharscin Pharma

List of Tables

Table 1. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (US$ Million) Growth Rate by Type (2020 & 2024 & 2031)

Table 2. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (US$ Million) Comparison by Sales Channel (2020 & 2024 & 2031)

Table 3. Global Market Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size (US$ Million) by Region:2020 VS 2024 VS 2031

Table 4. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) by Region (2020-2025)

Table 5. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Region (2020-2025)

Table 6. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) Market Share by Region (2020-2025)

Table 7. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Region (2020-2025)

Table 8. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) Forecast by Region (2026-2031)

Table 9. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share Forecast by Region (2026-2031)

Table 10. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) Forecast by Region (2026-2031)

Table 11. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share Forecast by Region (2026-2031)

Table 12. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (K Units) & (2020-2025)

Table 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Type (2020-2025)

Table 14. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (US$ Million) & (2020-2025)

Table 15. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (USD/Unit) & (2020-2025)

Table 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (K Units) & (2026-2031)

Table 17. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (US$ Million) & (2026-2031)

Table 18. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (USD/Unit) & (2026-2031)

Table 19. Representative Players of Each Type

Table 20. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (K Units) & (2020-2025)

Table 21. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Sales Channel (2020-2025)

Table 22. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Sales Channel (US$ Million) & (2020-2025)

Table 23. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Sales Channel (USD/Unit) & (2020-2025)

Table 24. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (K Units) & (2026-2031)

Table 25. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Sales Channel (US$ Million) & (2026-2031)

Table 26. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Sales Channel (USD/Unit) & (2026-2031)

Table 27. New Sources of Growth in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Application

Table 28. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Company (K Units) & (2020-2025)

Table 29. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Company (2020-2025)

Table 30. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Company (US$ Million) & (2020-2025)

Table 31. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Company (2020-2025)

Table 32. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs as of 2024)

Table 33. Global Market Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Average Price by Company (USD/Unit) & (2020-2025)

Table 34. Global Key Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Manufacturing Sites & Headquarters

Table 35. Global Key Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Product Type & Application

Table 36. Global Key Manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, Date of Enter into This Industry

Table 37. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 38. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Company (2020-2025) & (K Units)

Table 39. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Company (2020-2025)

Table 40. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Company (2020-2025) & (US$ Million)

Table 41. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Company (2020-2025)

Table 42. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2020-2025) & (K Units)

Table 43. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2020-2025)

Table 44. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2020-2025) & (K Units)

Table 45. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2020-2025)

Table 46. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Company (2020-2025) & (K Units)

Table 47. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Company (2020-2025)

Table 48. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Company (2020-2025) & (US$ Million)

Table 49. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Company (2020-2025)

Table 50. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2020-2025) & (K Units)

Table 51. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2020-2025)

Table 52. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2020-2025) & (K Units)

Table 53. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2020-2025)

Table 54. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Company (2020-2025) & (K Units)

Table 55. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Company (2020-2025)

Table 56. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Company (2020-2025) & (US$ Million)

Table 57. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Company (2020-2025)

Table 58. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2020-2025) & (K Units)

Table 59. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type (2020-2025)

Table 60. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Sales Channel (2020-2025) & (K Units)

Table 61. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel (2020-2025)

Table 62. Bausch Health Company Information

Table 63. Bausch Health Description and Business Overview

Table 64. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 65. Bausch Health Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product

Table 66. Bausch Health Recent Development

Table 67. Allergan Company Information

Table 68. Allergan Description and Business Overview

Table 69. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 70. Allergan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product

Table 71. Allergan Recent Development

Table 72. Sebela Pharmaceuticals Company Information

Table 73. Sebela Pharmaceuticals Description and Business Overview

Table 74. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 75. Sebela Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product

Table 76. Sebela Pharmaceuticals Recent Development

Table 77. Astellas Pharmaceuticals Company Information

Table 78. Astellas Pharmaceuticals Description and Business Overview

Table 79. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 80. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product

Table 81. Astellas Pharmaceuticals Recent Development

Table 82. Amneal Pharms Company Information

Table 83. Amneal Pharms Description and Business Overview

Table 84. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 85. Amneal Pharms Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product

Table 86. Amneal Pharms Recent Development

Table 87. Pharscin Pharma Company Information

Table 88. Pharscin Pharma Description and Business Overview

Table 89. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)

Table 90. Pharscin Pharma Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product

Table 91. Pharscin Pharma Recent Development

Table 92. Production Base and Market Concentration Rate of Raw Material

Table 93. Key Suppliers of Raw Materials

Table 94. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors List

Table 95. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customers List

Table 96. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Trends

Table 97. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Drivers

Table 98. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Challenges

Table 99. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Restraints

Table 100. Research Programs/Design for This Report

Table 101. Key Data Information from Secondary Sources

Table 102. Key Data Information from Primary Sources

List of Figures

Figure 1. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Picture

Figure 2. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (US$ Million) by Type (2020 & 2024 & 2031)

Figure 3. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Type in 2024 & 2031

Figure 4. XIFAXAN Product Picture

Figure 5. Viberzi Product Picture

Figure 6. Lotronex Product Picture

Figure 7. Other Product Picture

Figure 8. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (US$ Million) by Sales Channel (2020 & 2024 & 2031)

Figure 9. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Sales Channel in 2024 & 2031

Figure 10. Hospitals Pharmacy Examples

Figure 11. Retail Pharmacy Examples

Figure 12. Other Examples

Figure 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Growth Rate (2020-2031) & (US$ Million)

Figure 15. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) Growth Rate (2020-2031)

Figure 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price Trends Growth Rate (2020-2031) & (USD/Unit)

Figure 17. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Report Years Considered

Figure 18. Global Market Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Size (US$ Million) by Region:2020 VS 2024 VS 2031

Figure 19. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Region: 2020 VS 2024

Figure 20. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) Growth Rate (2020-2031)

Figure 21. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) Growth Rate (2020-2031)

Figure 22. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) Growth Rate (2020-2031)

Figure 23. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) Growth Rate (2020-2031)

Figure 24. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (US$ Million) Growth Rate (2020-2031)

Figure 25. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) Growth Rate (2020-2031)

Figure 26. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Type (2020-2025)

Figure 27. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Type (2026-2031)

Figure 28. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Type (2026-2031)

Figure 29. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Sales Channel (2020-2025)

Figure 30. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Growth Rate by Sales Channel in 2020 & 2024

Figure 31. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Sales Channel (2026-2031)

Figure 32. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Sales Channel (2026-2031)

Figure 33. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Company (2024)

Figure 34. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Company (2024)

Figure 35. Global 5 Largest Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Players Market Share by Revenue in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs: 2020 & 2024

Figure 36. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 37. Manufacturing Cost Structure of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs

Figure 38. Manufacturing Process Analysis of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs

Figure 39. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Industrial Chain

Figure 40. Channels of Distribution (Direct Vs Distribution)

Figure 41. Distributors Profiles

Figure 42. Bottom-up and Top-down Approaches for This Report

Figure 43. Data Triangulation

Figure 44. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User